Risk of Thyroid Disorders in Patients with Gout and Hyperuricemia

Abstract

The risk of thyroid autoimmunity and thyroid dysfunction among patients with gout and hyperuricemia has not been well defined. This study was undertaken to examine the impact of gout and hyperuricemia on risk of thyroid disorders including thyroid autoimmunity and thyroid dysfunction. A population-based cross-sectional study was conducted to assess the risk of thyroid autoimmunity and thyroid dysfunction related to gout and hyperuricemia, which included 115 gout patients, 439 hyperuricemic patients, and 2 254 individuals without gout and hyperuricemia. A systematic review and meta-analysis of 14 observational studies was also done to systematically evaluate the risk of thyroid dysfunction among patients with gout and hyperuricemia. Findings from the cross-sectional study suggested a significantly increased risk of hypothyroidism among female gout patients (OR=2.44, 95% CI 1.15–5.17, p=0.02). Besides, gout could also substantially increase risk of Hashimoto’s thyroiditis in women (OR=3.15, 95% CI 1.53–6.49, p=0.002). The meta-analysis proved a considerably increased risk of hypothyroidism among both gout patients (OR=1.51, 95% CI 1.23–1.85, p<0.001) and hyperuricemic patients (OR=1.34, 95% CI 1.11–1.61, p=0.002). Moreover, this meta-analysis also suggested that gout could also significantly increase the risk of hyperthyroidism (OR=1.25, 95% CI 1.06–1.48, p=0.01). The findings from the study suggest increasing risk of hypothyroidism and Hashimoto’s thyroiditis among gout patients. Moreover, gout but not hyperuricemia is linked to increased risk of hyperthyroidism. More studies are warranted to elucidate the influence of gout and hyperuricemia on thyroid disorders.

Key words

thyroid dysfunction - Hashimoto’s thyroiditis - gout - hyperuricemia - risk factors

^* These two authors contributed equally to this work.

• References

• 1 Zimmermann MB, Boelaert K. Iodine deficiency and thyroid disorders. Lancet Diabetes Endocrinol 2015; 3: 286-295
• 2 Tomer Y. Mechanisms of autoimmune thyroid diseases: From genetics to epigenetics. Annu Rev Pathol 2014; 9: 147-156
• 3 Taylor PN, Albrecht D, Scholz A. et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol 2018; 14: 301-316
• 4 Smith TJ, Hegedus L. Graves’ Disease. N Engl J Med 2016; 375: 1552-1565
• 5 Delitala AP, Pilia MG, Ferreli L. et al. Prevalence of unknown thyroid disorders in a Sardinian cohort. Eur J Endocrinol 2014; 171: 143-149
• 6 Baumgartner C, da Costa BR, Collet TH. et al. Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation. Circulation 2017; 136: 2100-2116
• 7 Lillevang-Johansen M, Abrahamsen B, Jorgensen HL. et al. Over- and under-treatment of hypothyroidism is associated with excess mortality: A register-based cohort study. Thyroid 2018; 28: 566-574
• 8 Journy NMY, Bernier MO, Doody MM. et al. Hyperthyroidism, hypothyroidism, and cause-specific mortality in a large cohort of women. Thyroid 2017; 27: 1001-1010
• 9 Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol 2013; 1: 238-249
• 10 Delitala AP. Subclinical Hyperthyroidism and the Cardiovascular Disease. Horm Metab Res 2017; 49: 723-731
• 11 Cooper DS, Biondi B. Subclinical thyroid disease. Lancet 2012; 379: 1142-1154
• 12 Burch HB, Cooper DS. Management of Graves Disease: A Review. JAMA 2015; 314: 2544-2554
• 13 Antonelli A, Ferrari SM, Corrado A. et al. Autoimmune thyroid disorders. Autoimmun Rev 2015; 14: 174-180
• 14 So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol 2017; 13: 639-647
• 15 Capuano V, Marchese F, Capuano R. et al. Hyperuricemia as an independent risk factor for major cardiovascular events: A 10-year cohort study from Southern Italy. J Cardiovasc Med (Hagerstown) 2017; 18: 159-164
• 16 Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet 2016; 388: 2039-2052
• 17 Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: An update on prevalence and treatment options. BMC Med 2017; 15: 123
• 18 Disveld IJM, Fransen J, Rongen GA. et al. Crystal-proven Gout and Characteristic Gout Severity Factors are Associated with Cardiovascular Disease. J Rheumatol 2018; 45: 858-863
• 19 Vincent ZL, Gamble G, House M. et al. Predictors of Mortality in People with Recent-onset Gout: A Prospective Observational Study. J Rheumatol 2017; 44: 368-373
• 20 Grayson PC, Kim SY, LaValley M. et al. Hyperuricemia and incident hypertension: A systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011; 63: 102-110
• 21 Durward WF. Letter: Gout and hypothyroidism in males. Arthritis Rheum 1976; 19: 123
• 22 Erickson AR, Enzenauer RJ, Nordstrom DM. et al. The prevalence of hypothyroidism in gout. Am J Med 1994; 97: 231-234
• 23 See LC, Kuo CF, Yu KH. et al. Hyperthyroid and hypothyroid status was strongly associated with gout and weakly associated with hyperuricaemia. PLoS One 2014; 9: e114579
• 24 Kuo CF, Grainge MJ, Mallen C. et al. Comorbidities in patients with gout prior to and following diagnosis: Case-control study. Ann Rheum Dis 2016; 75: 210-217
• 25 Zhang J, Meng Z, Zhang Q. et al. Gender impact on the correlations between subclinical thyroid dysfunction and hyperuricemia in Chinese. Clin Rheumatol 2016; 35: 143-149
• 26 Bruderer SG, Meier CR, Jick SS. et al. The association between thyroid disorders and incident gout: population-based case-control study. Clin Epidemiol 2017; 9: 205-215
• 27 Mao Y, Liu Z, Wang X. et al. Relationship between the prevalence of hyperuricemia and thyroid dysfunction. Clin J Rheumatol 2009; 13: 528-530
• 28 Ashizawa K, Imaizumi M, Usa T. et al. Metabolic cardiovascular disease risk factors and their clustering in subclinical hypothyroidism. Clin Endocrinol (Oxf) 2010; 72: 689-695
• 29 Chuang MH, Liao KM, Hung YM. et al. Abnormal thyroid-stimulating hormone and chronic kidney disease in elderly adults in Taipei City. J Am Geriatr Soc 2016; 64: 1267-1273
• 30 Peeters RP. Subclinical hypothyroidism. N Engl J Med 2017; 376: 2556-2565
• 31 Pearce SH, Brabant G, Duntas LH. et al. ETA Guideline: Management of Subclinical Hypothyroidism Eur. Thyroid J 2013; 2013: 215-228
• 32 Jonklaas J, Bianco AC, Bauer AJ. et al. Guidelines for the treatment of hypothyroidism: Prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid 2014; 24: 1670-1751
• 33 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009; 339: b2535
• 34 Margulis AV, Pladevall M, Riera-Guardia N. et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: The Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol 2014; 6: 359-368
• 35 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
• 36 Higgins JP, Thompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
• 37 Egger M, Davey Smith G, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
• 38 Peters JL, Sutton AJ, Jones DR. et al. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med 2007; 26: 4544-4562
• 39 Yao X, Nie X, Sun L. Relationship between gout and thyroid hormone. J Tianjin Med Univ 2012; 18: 78-80
• 40 Huang R, Cao Q, Gu J. et al. Clinical research of relationship between subclinical thyroid dysfunction and hyperuricemia. J Shanghai Jiaotong Univ (Medical Science) 2013; 33: 1348-1355
• 41 Nie X, Yao X, Sun L. The change of thyroid hormones and leptin at hyperuricemia and gout. J Chin Physician 2014; 16: 612-615
• 42 Singh JA, Cleveland JD.Gout. and Hypothyroidism in the Elderly: An observational cohort study using U.S. medicare claims data. J Gen Intern Med 2018; 33: 1229-1231
• 43 Nikolenko IuI, Nikolenko V, Ignatenko GA. et al. [Disfunction of thyroid gland at experimental hyperuricemia]. Biomed Khim 2005; 51: 72-75
• 44 Blake DR, McGregor AM, Stansfield E. et al. Antithyroid-antibody activity in the snyovial fluid of patients with various arthritides. Lancet 1979; 2: 224-226
• 45 Sato A, Shirota T, Shinoda T. et al. Hyperuricemia in patients with hyperthyroidism due to Graves’ disease. Metabolism 1995; 44: 207-211
• 46 Saini V, Yadav A, Arora MK. et al. Correlation of creatinine with TSH levels in overt hypothyroidism – A requirement for monitoring of renal function in hypothyroid patients?. Clin Biochem 2012; 45: 212-214
• 47 Yazar A, Doven O, Atis S. et al. Systolic pulmonary artery pressure and serum uric acid levels in patients with hyperthyroidism. Arch Med Res 2003; 34: 35-40
• 48 Perez-Ruiz F, Chinchilla SP, Atxotegi J. et al. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase. Rheumatol Int 2015; 35: 1857-1861
• 49 Merdler-Rabinowicz R, Tiosano S, Comaneshter D. et al. Comorbidity of gout and rheumatoid arthritis in a large population database. Clin Rheumatol 2017; 36: 657-660
• 50 Pakpoor J, Seminog OO, Ramagopalan SV. et al. Clinical associations between gout and multiple sclerosis, Parkinson’s disease and motor neuron disease: record-linkage studies. BMC Neurol 2015; 15: 16
• 51 Jeong JH, Hong S, Kwon OC. et al. CD14(+) cells with the phenotype of infiltrated monocytes consist of distinct populations characterized by anti-inflammatory as well as pro-inflammatory activity in gouty arthritis. Front Immunol 2017; 8: 1260